Drug intelligence / Profile preview

THDBH151

Development stage: Unknown
Lead developer: Tonghua Dongbao
Modality: Small Molecules
Administration: Oral

Overview

**THDBH151** is an orally administered small-molecule dual inhibitor of xanthine oxidase and urate transporter 1 being developed by Tonghua Dongbao and its subsidiary Dongbao Zixing for gout and hyperuricemia. It lowers serum urate through two complementary mechanisms: inhibition of xanthine oxidase reduces uric acid production, while inhibition of renal urate transporter 1 reduces tubular urate reabsorption and promotes urinary uric acid excretion. The program completed a Phase IIa trial in patients with gout, in which once-daily THDBH151 reduced serum uric acid with a dose-response relationship.

Other names: THDBH150/THDBH151

Targets

URAT1 (Uric Acid Transporter 1)XO (Xanthine Oxidoreductase)

Beyond the preview

Go deeper on THDBH151.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on THDBH151.

Explore the full profile